| 102.67 -4.15 (-3.89%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 123.41 |
1-year : | 130.75 |
| Resists | First : | 105.66 |
Second : | 111.94 |
| Pivot price | 102.33  |
|||
| Supports | First : | 95.5 |
Second : | 79.46 |
| MAs | MA(5) : | 101.09 |
MA(20) : | 102.95 |
| MA(100) : | 92.46 |
MA(250) : | 82.82 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 36.9 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 112.87 | Low : | 55.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVL ] has closed below upper band by 47.0%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 106.72 - 107.24 | 107.24 - 107.75 |
| Low: | 98.95 - 99.58 | 99.58 - 100.2 |
| Close: | 101.49 - 102.5 | 102.5 - 103.5 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Wed, 07 Jan 2026
Will Nuvalent’s Momentum Continue? - StocksToTrade
Wed, 07 Jan 2026
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock - Investing.com
Wed, 07 Jan 2026
Nuvalent (NUVL) chief development officer sells $721k in stock - Investing.com
Thu, 01 Jan 2026
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Tue, 23 Dec 2025
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Tue, 23 Dec 2025
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 103.2 (%) |
| Shares Short | 4,890 (K) |
| Shares Short P.Month | 4,470 (K) |
| EPS | -5.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -264 (M) |
| Levered Free Cash Flow | -133 (M) |
| PE Ratio | -19.27 |
| PEG Ratio | 0 |
| Price to Book value | 8.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|